Hybribody, the future of single-domain antibodies



May 9, 2016

  • Share
  • HYBRIBODY offers single-domain antibody selection and validation services. We handle the in vitro selection of antibodies against your protein from a fully synthetic humanized VHH library by an optimized Phage Display technology. VHHs have the advantages of being very small (15 kDa), affine and stable molecules. We validate the selected VHHs for in vitro and in vivo applications (ELISA, IF, Intrabody…). We are also able to fuse them with Fc fragments from the species of your choice to deliver fully-functional recombinant antibodies.
    More information on Hybribody is available on the dedicated website: www.hybribody.com

    Cancer ResearchCell ScienceImaging/MicroscopyImmunology

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.